UK deciding to leave the European Union could put the planned $30 billion merger between the London Stock Exchange and Germany’s Deutsche Börse at risk.
German regulators contested plans for a merged Deutsche Boerse-London Stock Exchange to be based in London following Britain’s vote to leave the European Union, while one politician even said the deal was now as good as dead.
Deutsche Boerse and LSE agreed in March to a $30 billion merger to create a European trading powerhouse that would be domiciled in Britain with headquarters in both London and Frankfurt.
Two German regulatory sources told Reuters on Friday, however, that there was increasing scepticism about London being the base for the holding company of the combined group.
“There is rising irritation and increasing concern that London as a base poses a problem,” one of the sources said after the Brexit vote.
The exchange regulator in the German state of Hesse, where Deutsche Boerse is based and which has the power to block the deal, declined to comment.
The state minister to whom the regulator answers, however, said Brexit would play a role in the decision about whether to approve the deal.
“We will take account of yesterday’s decision in our review,” Tarek Al-Wazir wrote on his Facebook page. “We will wait and see whether the plans remain in their current form.”
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Norton Rose Adds Antitrust Partners in Italy
Jan 20, 2025 by
CPI
Antitrust Lawsuit Over Google’s Search Monopoly Proceeds in CA Court
Jan 20, 2025 by
CPI
Digital Markets Act at Two Years: Enforcement in a Shifting Political Climate
Jan 20, 2025 by
CPI
EU Expands Tech Oversight with Updated Anti-Hate Speech Code
Jan 20, 2025 by
CPI
Cargill Settles Turkey Price-Fixing Lawsuit for $32.5 Million
Jan 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
CPI
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
CPI
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
CPI